Century Therapeutics, Inc.
IPSC
$0.51
-$0.02-3.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -16.13% | 1.05% | |||
| Gross Profit | 16.13% | -132.52% | |||
| SG&A Expenses | -12.43% | -7.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.30% | -0.93% | |||
| Operating Income | 15.30% | -146.73% | |||
| Income Before Tax | -5.78% | -142.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.78% | -142.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.78% | -142.50% | |||
| EBIT | 15.30% | -146.73% | |||
| EBITDA | 16.63% | -140.65% | |||
| EPS Basic | -5.51% | -142.39% | |||
| Normalized Basic EPS | 15.22% | -142.39% | |||
| EPS Diluted | -5.26% | -142.70% | |||
| Normalized Diluted EPS | 15.22% | -142.43% | |||
| Average Basic Shares Outstanding | 0.26% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||